Antibody cocktail given to patient in Ahmedabad

The monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight harmful pathogens and is to be administered for the treatment of mild to moderate Covid-19 in adults and paediatric patients (12 years or older), who are at high risk of developing severe disease.

“The monoclonal antibodies cocktail treatment was launched in India last week for treating mild Covid-19 patients… The patient we administered the combination medication today has diabetes, and hence belongs to the high-risk group… This medication is not recommended for Covid-19 patients who have moderate or severe disease with hypoxia,”
said Dr Surabhi Madan, Head of Department, Infectious Diseases Department, CIMS Hospital.